Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma.

Wu, Gujie; Hu, Qin; Chen, Hongyu; He, Min; Ma, Huiyun; Zhou, Lin; Xu, Kun; Ren, Hefei; Qi, Juntao

Wu, Gujie; Hu, Qin; Chen, Hongyu; He, Min; Ma, Huiyun; Zhou, Lin; Xu, Kun; Ren, Hefei; Qi, Juntao.

Affiliation

Wu G; Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Hu Q; Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Chen H; Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
He M; Research Center of Clinical Medicine, Shenzhen Hospital of Shanghai University of Traditional Chinese Medicine, Shenzhen, China.
Ma H; Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Zhou L; Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Xu K; Research Center of Clinical Medicine, Shenzhen Hospital of Shanghai University of Traditional Chinese Medicine, Shenzhen, China.
Ren H; Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Qi J; Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.

Front Oncol ; 13: 1127768, 2023.

Article in En | MEDLINE | ID: mdl-37007124

Key words

cuproptosis; immunotherapy; lung adenocarcinoma; prognosis; tumor microenvironment

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Front Oncol Year: 2023 Document type: Article Affiliation country: China Country of publication: Suiza

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google